Simultaneously, and in line with previous findings33, we observed a considerable decrease of tumour-resident CCR2+ myeloid cells (Extended Data Fig. 8b,c) and macrophages following aNP18-siCCR2 treatment compared with aNP18-siCtrl (Fig. 4m,n), without impacting tumour size (Extended Data Fig. 8d). Here, CCR2 is linked to neoplasm.